Single-pill full antiretroviral regimen shown better at controlling HIV and boosting CD4 cells
January 20 2006 12:00 AM EST
January 19 2006 3:21 AM EST
\n regimen outperforms gold standard\u003C/p>\n\n","image":{"@type":"ImageObject","height":600,"url":"https://www.advocate.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8zMjg0MjU0OC9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcxNDcxMzQ4MH0.rZo95Jiq6Ph8PVSZjmnPedqpyEz0RwIhb9oRpSZVIHg/image.png?width=210","width":1200},"keywords":[],"mainEntityOfPage":{"@id":"https://www.advocate.com/health/health-news/2006/01/20/one-pill-hiv-regimen-outperforms-gold-standard","@type":"WebPage"},"publisher":{"@type":"Organization","logo":{"@type":"ImageObject","url":"https://www.advocate.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8zMjg0MjU0OC9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcxNDcxMzQ4MH0.rZo95Jiq6Ph8PVSZjmnPedqpyEz0RwIhb9oRpSZVIHg/image.png?width=210"},"name":"Advocate.com"},"url":"https://www.advocate.com/health/health-news/2006/01/20/one-pill-hiv-regimen-outperforms-gold-standard"}
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Single-pill full antiretroviral regimen shown better at controlling HIV and boosting CD4 cells
Drugmakers Gilead Sciences and Bristol-Myers Squibb earlier this month announced success in combining their drugs Sustiva, Viread, and Emtriva into a single pill that is taken just once per day. Now a study in The New England Journal of Medicine shows that this simplified regimen is more effective at controlling HIV in treatment-naive patients than even the current gold standard of nonnucleoside reverse transcriptase inhibitor-based therapy.
Lead by researchers at Johns Hopkins University, the study showed that the Sustiva-Viread-Emtriva combination did a better job of reducing HIV viral levels and increasing CD4-cell counts after one year of treatment that the gold-standard combination of Sustiva plus Retrovir and Epivir. Also, fewer individuals on the one-pill regimen dropped out of the study due to adverse events.
Both nonnucleoside-based regimens are currently recommended by the Department of Health and Human Services for the treatment of HIV-positive adults just beginning antiretroviral therapy. But the current study of 517 treatment-naive HIV patients is the first to directly compare the two.
Study data showed that 84% of those taking the Sustiva-Viread-Emtriva combination pill were able to maintain an HIV viral load below 400 copies per milliliter of blood, compared to 73% of those on the Sustiva-Retrovir-Epivir combination. About 80% of those in the Sustiva-Viread-Emtriva arm suppressed HIV levels even further, to below 50 copies, compared to 70% of those taking Sustiva-Retrovir-Epivir.
Patients taking the one-pill combination also posted a mean increase in CD4-cell count of 190 cells, compared to a 158-cell increase among those taking Sustiva-Retrovir-Epivir.
Only 10 of the 257 patients (about 4%) taking Sustiva-Viread-Emtriva dropped out of the study due to adverse events, compared to 23 of the 254 (about 9%) of those taking Sustiva-Retrovir-Epivir.
Anecdotal data also suggested that fat loss from the extremities, a common side effect of antiretroviral therapy, occurred less often among patients in the single-pill regimen arm of the study. But the researchers say that because they did not collect body-fat measurements of the study subjects before beginning drug treatment they cannot quantify their observations.
Because the single-pill combination was shown to be more effective than Sustiva-Retrovir-Epivir combination, and in light of the ease of one-pill, once-daily dosing, the researchers say it is likely the Sustiva-Viread-Emtriva combo pill will be favored by many HIV doctors and patients when it becomes available. Officials at Gilead and BMS say they plan to submit a marketing application to the Food and Drug Administration this spring. If approved, the single-pill regimen could be available in the United States by the end of the year. (Advocate.com)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!